Effects of fluoxetine on NEGR1 expression in major depressive disorder patients

Creative Commons License

Akdeniz G. B., Bayoğlu B., Kocabaşoğlu N., Aksoy Poyraz C., Cengiz M.

ULUSLARARASI VIImoleküler TIP KONGRESİ, cilt.1, sa.7, ss.71-73, 2019 (Hakemli Dergi)

Özet

Effects of fluoxetine on NEGR1 expression in

major depressive disorder patients

71

A retrospective chart analysis. World J Gastrointest

Oncol Published Online First: 2016.

doi:10.4251/wjgo.v8.i9.688

OP20

Effects of fluoxetine on NEGR1 expression in

major depressive disorder patients

Gulseren Billur Akdeniz1, Burcu Bayoglu1, Nese

Kocabasoglu2, Cana Aksoy Poyraz2, Mujgan

Cengiz1

1Istanbul University-Cerrahpasa, Cerrahpasa

Medical Faculty, Department of Medical Biology,

Istanbul, Turkey.

2Istanbul University-Cerrahpasa, Cerrahpasa

Medical Faculty, Department of Psychiatry,

Istanbul, Turkey.

*Corresponding Author

Burcu Bayoglu, Ph.D., Associate Professor Istanbul

University-Cerrahpasa, Cerrahpasa Medical

Faculty, Department of Medical Biology, 34098,

Istanbul, Turkey, Tel: 00 90 (212) 414 30 00/22207,

Fax: 00 90 (212) 414 30 42,

burcubayoglu@yahoo.com;

burcu.bayoglu@istanbul.edu.tr

Introduction

Major depressive disorder (MDD) is a psychiatric

disorder which is characterized by sadness, loss of

interest or pleasure [1]. In 2017, the prevalence of

depression was 4.4% in Turkey[2].

According to a study conducted in European

individuals with MDD, one of 15 genetic loci

associated with MDD was NEGR1[3].

NEGR1 regulates neurite outgrowth and

participate in synapse formation[4]. In a study,

NEGR1, which was in 1p31.1 to 1p31.3 deletion,

was associated with hyperactivity disorder,

learning disability, speech and language

development[5], dyslexia[6]. NEGR1 gene

polymorphisms have also been associated with Human NEGR1, Houston, Texas, USA) following the

manufacturer’s instructions. Statistical analysis

were performed by using SPSS 21.0 program.